Distinction between short-segment Barrett’s esophageal and cardiac intestinal metaplasia

Table 1 Phenotype of IM at different sites

		subtype of IM
Site of IM	n	type I (%)	type II (%)	type III (%)
LSBE	28	3(10.71)	4(14.29)	21(75.00)ac
SSBE	30	7(23.33)	4(13.33)	19(63.33)ab
CIM	26	11(42.31)	9(34.62)	6(23.08)
GA-IM	34	18(52.94)	10(29.41)	6(17.65)

^aP<0.005 vs GA-IM;

^bP<0.01,

^cP<0.005 vs CIM

Table 2 CK7/20 immumoreactivity pattern of IM at defferent site

Site of IM	n	Barrett's CK7/20	Gastric CK7/20
		pattern	pattern
LSBE	28	22(78.57%) a	4(14.29%) a	2(7.14%)
SSBE	30	22(73.33%) a	4(13.33%) a	4(13.33%)
CIM	26	7(26.92%)	15(57.69%)	4(15.38%)
GA-IM	34	6(17.65%)	24(70.59)	4(11.76%)

^aP< 0.005 vs CIM

Table 3 Relationships betweeen CK7/20 immunoreactivity patterns and symptoms of GERD and H pylori infection

	Barett's CK7/20	Gastric CK7/20	Other pattern
	pattern(=57)(%)	pattern (=47) (%)	(=14)(%)
Symptoms of GERD	49(85.96)a	10(21.28)	3(21.43)
H pylori infection	11(19.30)a	30(63.83)	4(28.57)

^aP<0.005 vs Gastric CK / 20 pattern